CHARACTERISTIC OF PNEUMOCOCCAL POST-VACCINATION IMMUNITY IN HIV-POSITIVE PATIENTS THROUGH 2 YEARS AFTER IMMUNIZATION

Abstract

At present, the problem of vaccination of HIV-infected patients from pneumococcal disease is still poorly studied. There is no consensus on the effectiveness of immunization, the appropriateness and timing of revaccination. The aim of the study was to examine the duration and power of post-vaccination pneumococcal immunity in HIV-infected adult patients. A prospective comparative randomized study was performed, 100 HIV-infected patients were vaccinated with a polysaccharide 23-valent pneumococcal vaccine. Comparison group was consisted of 100 cases, not vaccinated against pneumococcal infection. For detection of the power of immunity through 2 years blood serum level of IgG antibodies to a mixture ofpolysaccharides (SP) S. pneumoniae incorporated in the vaccine were determined, the comparison of the incidence of acute respiratory infections, pneumonia and bronchitis was carried out, and their etiological transcript with the help of bacteriological examination of sputum was performed. The obtained results indicate to the powerful post-vaccination immunity with the high level of seroprotection and significant preventive effect through two years after vaccination.

Keywords

HIV-infection / pneumococcal immunity

References

[1] Козлов Р.С. Пневмококки: уроки прошлого - взгляд в будущее. Смоленск: Смоленская медицинская академия; 2010.

[2] Whitney C.J., Farlej M.M., Halder J. et.al. Decline in invasive pneumococcal disease after the introduction of protein-poljsaccharide conjugate vaccine. N. Engl. J. Med. 2003; 348 (18): 1737-46.

[3] Kyaw M.H., Rose C.T. Jr., Try A.M. et al. The influence of chronic illness on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 2005; 192 (3): 377-86.

[4] Rivera-Matos J.R., Rios-Olivares E. A multicenter hospital surveillance of invasive streptocjccus pneumonia, Puerto Rico, 2001. P.R. Hlth Sci. J. 2005; 24 (3): 185-9.

[5] Brichacek B., Swindells S., Janoff E.N. et al. Increased plasma human immunodeficiency virus type I burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 1996; 174: 1191-9.

[6] Rubin L.G. Pneumococcal vaccine. Pediatr. Clin. N. Am. 2000; 47 (2): 269-85.

[7] Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. М.; 2009.

[8] Чучалин А.Г. Белая книга. Пульмонология. 2004: 1456-67.

[9] French N, Nakiyingi J., Carpenter L.M. et al. 23—valent pneumococcal polysaccharide vaccine in YIV-T_Infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet. 2000; 355: 2106-11.

[10] Таточенко В.К. Пневмококковая инфекция вошла в число управляемых. Журнал микробиологии, эпидемиологии и иммунобиологии. 2010; 3: 102-8.

[11] Couch R.B. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin. Infect. 1999; 28: 548-51.

[12] Николенко В.В., Фельдблюм И.В., Воробьева Н.Н. Оценка ре-актогенности и иммуногенности пневмококковой вакцины при иммунизации взрослых ВИЧ-позитивных пациентов. В кн.: Материалы IV ежегодного Всероссийского конгресса по инфекционным болезням. М.; 2012.

[13] Костинов М.П. Иммунокоррекция вакцинального процесса у лиц с нарушенным состоянием здоровья. М.; 2006.

[14] Pneumococcal conjugate vaccine for childhood immunization. Weekly Epidemiol. Rec. 2007; 82 (12): 93-104.

[15] Николенко В.В., Фельдблюм И.В., Шмагель Н.Г., Иванова Э.С., Варецкая Т.А., Старкова В.И., Хафизов К.М., Юрганова Г.А., Моисеева Г.В. Профилактическая эффективность вакцинации ВИЧ-позитивных пациентов от инфекции, обусловленной Streptococcus pneumonia. В кн.: Материалы V ежегодного Всероссийского конгресса по инфекционным болезням. М.; 2013.

RIGHTS & PERMISSIONS

Eco-vector